Pulse Biosciences, Inc. PLSE

Company Overview

Pulse Biosciences, Inc. is a U.S.-based medical technology company focused on developing and commercializing therapeutic applications that use ultra-short pulsed electric fields, marketed under its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology platform. The company operates within the medical device and bioelectric medicine industries, with primary emphasis on electrophysiology, surgical oncology, dermatology, and soft tissue treatment applications. Pulse Biosciences’ technology is designed to deliver non-thermal electrical energy in nanosecond durations to selectively affect cellular structures while minimizing collateral tissue damage compared with some conventional thermal-based ablation methods.

The company’s principal revenue drivers remain tied to the development, regulatory advancement, and commercialization of its nsPFA systems and associated disposable devices. Pulse Biosciences has historically focused on investigational and early commercial opportunities involving cardiac ablation and tumor treatment technologies. The company was founded in 2014 and is headquartered in Hayward, California. Its evolution has centered on expanding applications for pulsed electric field technologies across multiple medical specialties, with strategic emphasis on minimally invasive procedures and next-generation energy delivery systems.

Business Operations

Pulse Biosciences organizes its operations primarily around the development and commercialization of its CellFX and nsPFA-based platforms. The company generates revenue principally through the sale or evaluation use of capital equipment, disposable handpieces, and related procedural technologies, although commercial revenue has historically remained limited relative to research and development expenditures. Its operations are concentrated in medical device innovation, clinical evaluation, regulatory activities, physician training, and technology validation.

The company’s activities are primarily based in the United States, though it has pursued clinical collaborations and regulatory engagement that may support broader international expansion. Pulse Biosciences controls proprietary intellectual property related to pulse generators, waveform delivery systems, and energy-based ablation technologies. Public filings and investor materials identify collaborations with clinical investigators, hospitals, and electrophysiology specialists as central to development efforts. Data regarding material joint ventures or large-scale international subsidiaries is inconclusive based on available public sources.

Strategic Position & Investments

Pulse Biosciences’ strategic direction has focused on expanding the clinical applicability of nsPFA technology, particularly in cardiac electrophysiology and oncology. The company has invested substantially in research and development aimed at advancing pulsed field ablation systems for atrial fibrillation and other arrhythmia treatments, an area attracting increasing industry attention due to demand for safer and more tissue-selective ablation methods. The company has also explored applications in dermatology and surgical soft tissue therapies through its CellFX System platform.

Strategically, Pulse Biosciences has emphasized clinical validation, physician adoption, and regulatory progression rather than large-scale acquisition activity. Public disclosures indicate continuing investment in engineering development, clinical studies, manufacturing capabilities, and intellectual property expansion. The company’s positioning benefits from participation in the growing pulsed field ablation market, where multiple medical device companies are investing heavily in non-thermal ablation technologies. However, commercialization scale and competitive positioning remain dependent on regulatory approvals, procedural adoption, and clinical outcome data.

Geographic Footprint

Pulse Biosciences is headquartered in Hayward, California, and its operational footprint is primarily concentrated in the United States. The company’s clinical and commercial activities have largely centered on U.S.-based healthcare systems, physician networks, and regulatory pathways overseen by the U.S. Food and Drug Administration. Manufacturing, engineering, and corporate operations are also principally domestic based on public disclosures.

While Pulse Biosciences does not currently maintain the same global commercial infrastructure as larger multinational medical device companies, it has pursued visibility within international medical conferences and electrophysiology communities. Its technologies target markets with global demand potential, including North America, Europe, and parts of Asia-Pacific, particularly in cardiac ablation and oncology treatment sectors. Publicly available information does not indicate significant international operational subsidiaries or extensive foreign manufacturing operations at this time.

Leadership & Governance

Pulse Biosciences is led by a management team with backgrounds in medical technology, commercialization, finance, and healthcare innovation. The company’s governance structure includes executive leadership and a board of directors overseeing strategic development, regulatory progress, and capital allocation. Public company disclosures and SEC filings indicate a strategic emphasis on advancing nsPFA technology toward broader clinical adoption while maintaining investment in product development and physician engagement.

Key executives include:

• Paul A. LaViolette – Executive Chairman
• Kevin Danahy – Chief Executive Officer
• Anji Maram – Chief Financial Officer
• Darrin Uecker – Former Chief Executive Officer and senior technology leader associated with the company’s development efforts

Leadership communications have consistently emphasized innovation in bioelectric medicine, expansion of clinical evidence, and long-term commercialization opportunities in pulsed field ablation technologies.